Asset
Azetukalner
Xenon Pharmaceuticals Inc. Common Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05614063 | phase3 | completed | 2022-11-18 | 2026-01-12 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
| NCT05716100 | phase3 | recruiting | 2023-05-09 | 2026-10-01 | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |
| NCT03796962 | phase2 | active_not_recruiting | 2019-01-30 | 2021-09-02 | Xenon Pharmaceuticals Inc. | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy |
| NCT05667142 | phase3 | recruiting | 2023-02-14 | 2027-04-01 | Xenon Pharmaceuticals Inc. | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures |
| NCT05376150 | phase2 | completed | 2022-05-19 | 2023-09-18 | Xenon Pharmaceuticals Inc. | A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder |
FDA applications (0)
This company has no applications containing this asset.